Chemed stock falls after weaker than expected Florida Medicare results

Published 06/30/2025, 11:26 AM
© Reuters.

Investing.com -- Chemed Corporation (NYSE:CHE) stock fell 14% after the company reported weaker-than-expected Medicare admissions in Florida, leading to projected revenue limitations for its VITAS subsidiary.

The healthcare services provider now projects a Medicare Cap revenue limitation of $18 million to $25 million for the 2025 government fiscal year related to its Florida consolidated program, excluding Tallahassee. Previous guidance for 2025 earnings did not include any Florida Medicare Cap limitations.

The company cited two factors contributing to the Medicare Cap issue. First, its "community access" program, which has driven higher-than-average ADC and revenue growth over the past two years, adds pressure due to patients accessing hospice care earlier. Second, a rate differential between the national Medicare Cap per admission increase (2.9%) and the Florida consolidated program reimbursement increase (5.2%) negatively impacts calculations by approximately $25 million.

Additionally, Chemed reported unexpected weakness in Roto-Rooter’s residential business demand during the second quarter, breaking from trends seen in the first quarter of 2025. While commercial demand showed improved trends, it wasn’t enough to offset lower residential demand.

RBC Capital analyst Ben Hendrix lowered the price target on Chemed to $640 from $674 while maintaining an Outperform rating. "While we are disappointed to see Medicare cap limitations weigh on the 2025 outlook, we are encouraged by VITAS’ new CON, which should help the company maintain strong positioning in an increasingly competitive FL market, while providing an incremental lever to better manage cap pressure going forward," Hendrix commented.

The company noted that on June 20, VITAS received a Certificate of Need to begin operating in Pinellas County, Florida, which represents a significant opportunity for growth and Medicare Cap mitigation in 2026 and beyond.

Chemed will release its second quarter financial results on July 29, 2025, after market close.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.